The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 09, 2016
Filed:
Mar. 09, 2013
Applicant:
Moderna Therapeutics, Inc., Cambridge, MA (US);
Inventors:
Stephane Bancel, Cambridge, MA (US);
Tirtha Chakraborty, Medford, MA (US);
Antonin de Fougerolles, Waterloo, BE;
Sayda M. Elbashir, Cambridge, MA (US);
Matthias John, Cambridge, MA (US);
Atanu Roy, Stoneham, MA (US);
Susan Whoriskey, Belmont, MA (US);
Kristy M. Wood, Cambridge, MA (US);
Paul Hatala, Charlestown, MA (US);
Jason P. Schrum, Philadelphia, PA (US);
Kenechi Ejebe, New York, NY (US);
Jeff Lynn Ellsworth, Lexington, MA (US);
Justin Guild, Framingham, MA (US);
Assignee:
Moderna Therapeutics, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 38/17 (2006.01); A61K 31/7115 (2006.01); A61K 9/127 (2006.01); A61K 48/00 (2006.01); C12N 9/64 (2006.01); C07K 14/515 (2006.01); C07K 16/00 (2006.01); C07K 14/535 (2006.01); A61K 38/45 (2006.01); C07K 14/005 (2006.01); C07K 14/435 (2006.01); C07K 14/485 (2006.01); C07K 14/505 (2006.01); C07K 14/62 (2006.01); C07K 14/705 (2006.01); C12N 9/10 (2006.01); C12N 9/16 (2006.01); C12N 9/24 (2006.01); C12N 9/42 (2006.01); C12N 9/88 (2006.01); C12N 9/00 (2006.01); C12N 15/11 (2006.01); C12N 15/52 (2006.01); C12N 15/85 (2006.01); C12N 15/87 (2006.01); C12P 13/04 (2006.01); C12P 21/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/177 (2013.01); A61K 9/1271 (2013.01); A61K 31/7115 (2013.01); A61K 38/17 (2013.01); A61K 38/45 (2013.01); A61K 48/005 (2013.01); A61K 48/0033 (2013.01); A61K 48/0066 (2013.01); C07K 14/005 (2013.01); C07K 14/435 (2013.01); C07K 14/47 (2013.01); C07K 14/4705 (2013.01); C07K 14/4713 (2013.01); C07K 14/485 (2013.01); C07K 14/505 (2013.01); C07K 14/515 (2013.01); C07K 14/535 (2013.01); C07K 14/62 (2013.01); C07K 14/705 (2013.01); C07K 16/00 (2013.01); C12N 9/1051 (2013.01); C12N 9/16 (2013.01); C12N 9/2402 (2013.01); C12N 9/2445 (2013.01); C12N 9/644 (2013.01); C12N 9/6451 (2013.01); C12N 9/88 (2013.01); C12N 9/93 (2013.01); C12N 15/11 (2013.01); C12N 15/52 (2013.01); C12N 15/85 (2013.01); C12N 15/87 (2013.01); C12P 13/04 (2013.01); C12P 21/00 (2013.01); A61K 38/00 (2013.01);
Abstract
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.